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FOXP3+ regulatory T cells (Tregs) represent a promising platform for effective adoptive 
immunotherapy of chronic inflammatory disease, including autoimmune diseases such as 
multiple sclerosis. Successful Treg immunotherapy however requires new technologies 
to enable long-term expansion of stable, antigen-specific FOXP3+ Tregs in cell culture. 
Antigen-specific activation of naïve T  cells in the presence of TGF-β elicits the initial 
differentiation of the FOXP3+ lineage, but these Treg lines lack phenotypic stability and 
rapidly transition to a conventional T cell (Tcon) phenotype during in vitro propagation. 
Because Tregs and Tcons differentially express CD25, we hypothesized that anti-CD25 
monoclonal antibodies (mAbs) would only partially block IL-2 signaling in CD25high 
FOXP3+ Tregs while completely blocking IL-2 responses of CD25low-intermediate Tcons to 
enable preferential outgrowth of Tregs during in vitro propagation. Indeed, murine TGF-β-
induced MOG-specific Treg lines from 2D2 transgenic mice that were maintained in IL-2 
with the anti-CD25 PC61 mAb rapidly acquired and indefinitely maintained a FOXP3high 
phenotype during long-term in vitro propagation (>90% FOXP3+ Tregs), whereas parallel 
cultures lacking PC61 rapidly lost FOXP3. These results pertained to TGF-β-inducible 
“iTregs” because Tregs from 2D2-FIG Rag1−/− mice, which lack thymic or natural Tregs, 
were stabilized by continuous culture in IL-2 and PC61. MOG-specific and polyclonal 
Tregs upregulated the Treg-associated markers Neuropilin-1 (NRP1) and Helios (IKZF2). 
Just as PC61 stabilized FOXP3+ Tregs during expansion in IL-2, TGF-β fully stabilized 
FOXP3+ Tregs during cellular activation in the presence of dendritic cells and antigen/
mitogen. Adoptive transfer of blastogenic CD25high FOXP3+ Tregs from MOG35-55-
specific 2D2 TCR transgenic mice suppressed experimental autoimmune encephalomy-
elitis in pretreatment and therapeutic protocols. In conclusion, low IL-2 concentrations 
coupled with high PC61 concentrations constrained IL-2 signaling to a low-intensity
range that enabled dominant stable outgrowth of suppressive CD25high FOXP3+ Tregs. 
The ability to indefinitely expand stable Treg lines will provide insight into FOXP3+ Treg 
physiology and will be foundational for Treg-based immunotherapy.
 
Keywords: rodent, FOXP3, regulatory T  cells, experimental autoimmune encephalomyelitis/Ms, tolerance, 
neuroimmunology
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inTrODUcTiOn
CD4+ CD25+ FOXP3+ regulatory T  cells (Tregs) mediate an 
integral role in controlling autoimmunity and chronic inflamma-
tory disorders (1, 2). The importance of Tregs is illustrated by 
loss-of-function mutations in Foxp3 that cause early-onset, fatal, 
multi-organ autoimmune disorders IPEX (immunodysregulation 
polyendocrinopathy enteropathy X-linked syndrome) in humans 
and scurfy in mice (3). Moreover, dysfunctional Treg responses 
have been implicated in susceptibility to several autoimmune 
diseases including multiple sclerosis and type 1 diabetes (4). 
Treg-mediated suppressive activity has promise for translation as 
an immunotherapy for autoimmune disease and other chronic 
inflammatory disorders. Treg adoptive immunotherapy is based 
on the concept that Tregs can be isolated or induced ex vivo, 
expanded as a stable subset in  vitro, and then infused into a 
syngeneic recipient to inhibit autoimmune inflammation. Treg 
immunotherapy has shown encouraging results in preclinical 
models of autoimmune disease such as experimental autoimmune 
encephalomyelitis (EAE), type 1 diabetes, and colitis (5–7). In 
early phase clinical trials, Treg-based immunotherapies for trans-
plantation and type 1 diabetes have had favorable outcomes (8, 9). 
However, adoptive Treg immunotherapy has yet to be approved 
as a treatment option due to technical limitations associated with 
Treg instability during in vitro expansion.
FOXP3 is expressed in a canonical lineage of suppressive 
Tregs and is an obligate requirement for adaptive self-tolerance. 
However, FOXP3+ Tregs exhibit phenotypic and functional 
plasticity (10, 11), which represents a primary obstacle for devel-
opment of Treg-based immunotherapy. In vivo fate-mapping 
studies that tracked FOXP3+ Tregs showed that strong cellular 
activation in pro-inflammatory environments caused the loss of 
the immunosuppressive FOXP3 phenotype, such that ex-Tregs 
downregulated FOXP3 expression and acquired effector function 
(12). Indeed, Treg lines lost FOXP3 expression when cultured in 
IL-2, especially when undergoing multiple in  vitro activations 
(13). The concern is that conversion of FOXP3+ Tregs to effec-
tor “ex-Tregs” may exacerbate autoimmune disease. Instability 
of Treg lineages may reflect intrinsic loss of the FOXP3+ Treg 
phenotype on a per cell basis. However, instability of continuous 
Treg lines may also reflect overgrowth of stable Tregs by effector 
T cells because Tregs exhibit proliferative anergy, whereas con-
ventional T cell (Tcon) subsets exhibit hyper-proliferative growth 
rates. Various therapeutic strategies have attempted to directly 
manipulate Treg stability by administration of low-dose IL-2 or 
IL-2/anti-IL-2 immune complexes to limit IL-2 availability and 
favor Treg responses in animal models and in the clinic (14–17). 
Additional studies revealed that the immunosuppressive drug 
rapamycin may favor predominance of Tregs over Tcon subsets 
(18). However, these strategies are not sufficient to derive Treg 
cultures suitable for adoptive immunotherapy.
Two distinct lineages of Tregs are defined based upon the site 
of initial differentiation (19). Thymically derived Tregs (tTregs) 
differentiate in the thymus whereas induced Tregs (iTregs) arise 
de novo in extrathymic tissues or are induced in vitro. The tTreg 
subset is advantageous because tTregs are thought to be more 
stable than iTregs (20, 21). Expansion of antigen-specific tTregs 
nonetheless is technically challenging because, like iTregs, tTregs 
gradually downregulate FOXP3 expression during cellular activa-
tion and in vitro expansion (13). The challenge is the derivation 
of antigen-specific lines of either Treg lineage, because antigen-
specific Tregs are more suppressive than non-specific polyclonal 
Tregs in antigen-bearing tissues (6, 22). Indeed, the use of iTregs, 
inducible by antigen, may provide advantages for derivation 
of antigen-specific Tregs. The hurdle is to achieve stability of 
TGF-β-iTregs during long-term in vitro culture so that one can 
exponentially expand rare antigen-specific clonotypes to achieve 
antigen-specific, stable FOXP3+ Treg lines. Derivation of antigen-
specific Tregs will require long-term clonotypic expansion 
in vitro, due to the limited frequencies of antigen-specific precur-
sors. The application of Tregs in adoptive immunotherapy for MS 
for example would hinge on the ability to stabilize myelin-specific 
iTregs during sustained cycles of propagation and reactivation, 
which is the main focus of this study.
IL-2 is necessary for maintenance of both Tregs and many 
Tcon subsets in vitro. Compared to other T cell lineages, Tregs 
have superior sensitivity to limited IL-2 concentrations because 
many FOXP3+ Tregs constitutively express superlative levels of 
the IL-2 receptor α chain CD25. Although some quasi-stable 
FOXP3+ T cells lack robust levels of CD25, the CD25high FOXP3+ 
phenotype represents a prototypic phenotypic marker for 
immunosuppressive Tregs. Although CD25 is also transiently 
expressed on activated effector T cell lineages, CD25 is rapidly 
down-regulated on Tcons during reversion to a quiescent resting 
state. The CD25high phenotype reflects a major immunoregulatory 
strategy because superlative CD25 expression enables Tregs to 
monopolize and consume the local IL-2 supply to ensure regional 
Treg dominance coupled with IL-2 starvation and death of Tcon 
subsets (23). In this regard, the IL-2/CD25 pathway may represent 
the critical regulatory nexus controlling the differential growth 
and survival of Treg and Tcon subsets. However, we currently 
lack an adequate understanding of how the IL-2/CD25 pathway 
controls the relative dynamics of Treg or Tcon growth.
Differential expression of CD25 and the consequent differ-
ences in IL-2 potency may provide a means to directly manipulate 
the balance of Treg and Tcon subsets in cell culture. This study is 
based on the hypothesis that CD25high FOXP3+ Tregs will exhibit 
relatively high degrees of resistance to CD25 blockade whereas 
CD25intermediate Tcon subsets will be fully susceptible to CD25 
blockade and will selectively die due to cytokine starvation. In 
support of this hypothesis, the anti-mouse CD25 monoclonal 
antibody (mAb) PC61 supported the differential expansion of 
FOXP3+ T cells and was the key agent necessary to generate long-
term, FOXP3+ Treg lines that were stable over several months of 
in vitro propagation. At high PC61 concentrations and low IL-2 
concentrations, IL-2-dependent Treg proliferation was dominant 
over Tcon proliferation, and these differential growth rates enabled 
Tregs to progressively dominate mixed cultures. Continuously 
propagated Treg lines progressively expressed Treg-associated 
markers Neuropilin-1 (NRP1) and Helios (IKZF2). Treg lines 
were reactivated in the presence of TGF-β and expanded in vitro 
in the presence of PC61 without showing any decrease in FOXP3 
expression as a percentage of the T cell population or on a per cell 
basis. Tregs propagated in culture for extended periods of time 
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retained suppressive capabilities as shown by in vitro suppression 




C57BL/6 mice, MOG35-55 specific TCR transgenic 2D2 mice 
[B6-Tg(Tcra2D2,Tcrb2D2)1Kuch/J] (Stock Number 006912), 
OVA323-339 specific TCR transgenic OT-II mice (Stock Number 
004194), B6.129S7-Rag1tm1Mom/J (Stock Number 002216), and 
Foxp3-IRES-GFP knock-in (FIG) mice (B6.Cg-Foxp3tm2Tch/J, 
Stock Number 006772) were obtained from Jackson Laboratory 
(Bar Harbor, ME, USA) and were maintained as a colony in the 
Department of Comparative Medicine. In the 2D2-FIG and 
OTII-FIG strains, the FIG GFP reporter was used as a surrogate 
marker of FOXP3 expression. Routine screening of 2D2 mice 
was performed by FACS analysis of PBMC by use of antibod-
ies specific for TCR Vβ11 and/or Vα3.2. Routine screening of 
OT-II mice was performed by FACS analysis of PBMC by use 
of antibodies specific for TCR Vβ5.1/5.2 and Vα2. The FIG 
genotype was screened by use of forward (CAC CTA TGC CAC 
CCT TAT CC) and reverse (ATT GTG GGT CAA GGG GAA G) 
primers. Animal care and use was performed in accordance with 
approved animal use protocols and guidelines of the East Carolina 
University Institutional Animal Care and Use Committee.
MOg35-55, OVa323-339, TgF-β, and il-2
Synthetic MOG35-55 (MEVGWYRSPFSRVVHLYRNGK) 
and OVA323-339 (ISQAVHAAHAEINEAGR) peptides were 
obtained from Genscript (Piscataway, NJ, USA). Recombinant 
rat TGF-β1 was expressed by use of transfected human embry-
onic kidney (HEK) cells. TGF-β1 was expressed as described 
(24, 25). This expression vector encoded a rat serum albumin 
leader sequence, an 8-histidine purification tag, the latency-
associated peptide (LAP), the native RHRR cleavage site, and the 
C-terminal TGF-β1 sequence. A C32S substitution in the LAP 
domain enabled high level expression. The protein was expressed 
in HEK supernatants, purified on Ni-NTA affinity columns, and 
was activated by 10 min of exposure to 70°C. The bioactivity of 
each TGF-β1 preparation was verified by induction of FOXP3 
in cultures of MOG-stimulated 2D2-FIG splenocytes (SPL). 
Recombinant rat IL-2 (~10–30 U/ml) was derived from a bacu-
lovirus expression system and was used routinely in bulk T cell 
culture (26). Recombinant murine IL-2 was purified from a stable 
transfected HEK293F cell line.
generation, Purification, and 
administration of mabs and Pc61scFv
The PC61-5.3 anti-CD25 rat IgG1(λ) hybridoma (27), the 7D4 
anti-CD25 rat IgM(κ) hybridoma, and the 1D11.16.8 anti-mouse-
TGF-β1/2/3 mouse IgG1 hybridoma (28, 29) were obtained from 
ATCC. The 3C7 anti-CD25 rat IgG2b(κ) hybridoma was a gener-
ous gift from Dr. Ethan Shevach (NIH). All hybridomas were 
subcloned twice to ensure stability. Hybridoma supernatants were 
clarified at 7,200 × g, precipitated with 50% ammonium sulfate, 
and dissolved in PBS. mAbs were purified on protein G agarose 
columns, eluted with 200 mM glycine at pH 3.0, and neutralized 
by 1 M Tris buffer of pH 9.0. The purity of these mAb was veri-
fied by SDS-PAGE. Specific activities of PC61 preparations were 
measured by staining of murine CD25+ T cells with serial 1/2 log 
dilutions of the mAb. After washing, PC61-stained T cells were 
labeled with a PE-conjugated goat anti-rat IgG (H + L) secondary 
antibodies followed by flow cytometric analysis.
The PC61scFv gene encoded (from N-terminus to C-terminus) 
the rat serum albumin signal peptide, a polyhistidine affin-
ity purification tag, the PC61 variable light chain domain, a 
(Glycine4Serine1)4 linker, and the PC61 variable heavy chain 
domain. The PC61 VL and VH domain sequences were described 
previously (30). The sequence was as follows: M-A-K-W-V-T-F-L-
L-L-L-F-I-S-G-S-A-F-S-H-H-H-H-H-H-H-H-H-(variable light 
chain domain)-G-G-G-G-S-G-G-G-G-S-G-G-G-G-S-G-G-G-G-
S-(variable heavy chain domain)-A-K-G-G-G-S-E-G-G-G-S-E-G-
G-G-S-G. The PC61scFv gene sequence was cloned into the pIRES 
AcGFP1 expression vector (Clontech) and used to stably transfect 
HEK293F cells. PC61scFv was purified using a column loaded 
with Ni-NTA resin, and purity was measured using SDS-PAGE. 
PC61scFv specificity and activity was validated by inhibition of 
IL-2-dependent proliferation of an IL-2-dependent cell line.
Flow cytometric analyses of sPl and 
PBMc
Cells were washed in HBSS with 2% heat-inactivated FBS and 
stained for 1  h at 4°C in the dark with designated cocktails of 
fluorochrome-conjugated antibodies, including those specific for 
Vβ11 (KT11), Vβ5.1 (MR9-4), CD25 (PC61), CD25 (3C7), LAP 
(TW7-16B4), GARP (F011-5), GITR (DTA-1), PD-1 (29F-1A12), 
Nrp1 (3E12), Helios (22F6), CD69 (H1.2F3), ICOS (C398.4A), 
CTLA4 (UC10-4B9), TIGIT (1G9), CD44 (IM7), CD62L (MEL-
14), CD45.1 (A20), and goat anti-rat IgG. Cells were then washed 
three times with HBSS/2% FBS. Data were collected by use of a 
Becton-Dickinson LSRII flow cytometer (San Jose, CA, USA) and 
analyzed by use of FlowJo software.
generation and Maintenance of Treg lines
Naïve SPL were harvested from 2D2-FIG mice, 2D2-FIG-Rag1−/− 
mice, OTII-FIG mice, or FIG mice. These SPL were activated at 
a density of 2 ×  106/ml in complete RPMI (cRPMI; 10% heat-
inactivated fetal bovine serum, 2  mM glutamine, 100  µg/ml 
streptomycin, 100  U/ml penicillin, 50  µM 2-ME) for 3–4  days 
with 1  µM MOG35-55, 100  nM OVA323-339, or 2.5  µg/ml 
Con-A, as indicated. Naïve FOXP3null T cells were isolated from 
2D2-FIG SPL by FACS to support the in vitro generation of TGF-
β-induced iTregs and thereby exclude the contribution of thymic/
natural tTregs/nTregs in designated experiments. After the initial 
activation, T cells were passaged every 3–4 days in rat IL-2 and 
were periodically reactivated every 2–4  weeks by reactivation 
with specific antigen or mitogen in a 3- to 4-day culture with 
irradiated splenic APC to drive cellular activation and expand 
T cell numbers. The initial activation also included 10 nM TGF-β 
to elicit Treg differentiation, but TGF-β was not added during the 
subsequent maintenance passages of the line in rat IL-2. PC61 or 
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a designated anti-CD25 antibody (10 µg/ml; 65 nM) was included 
in the activation and/or maintenance cultures as designated. Cells 
were propagated every 3–4 days in maintenance cultures contain-
ing cRPMI and rat IL-2 along with 10 µg/ml PC61 (or designated 
anti-CD25 antibody). For polyclonal Treg lines derived from FIG 
mice, CD4+ cells were purified 10 days post-activation using mag-
netic bead positive selection (Miltenyi Biotec). Unless otherwise 
noted, subsequent reactivation of Tregs consisted of co-culturing 
irradiated SPL (2 × 106/ml) and 2D2-FIG Tregs (2 × 105/ml) in 
the presence of 1 µM MOG35-55, TGF-β (as designated), and rat 
IL-2 with or without PC61 as designated. After 3 days, activated 
Tregs were passaged into cRPMI containing rat IL-2 and 10 µg/
ml PC61.
In Vitro suppression assay
CD45.2 2D2-FIG Tregs were cultured in PC61 and IL-2 for either 
13 or 40 days, and a control line of CD45.2 2D2-FIG Tcons were 
cultured in IL-2 for 13 days. These Treg and control lines were 
used to test the ability of Tregs to suppress naïve 2D2-FIG T cell 
activation. CTV-stained CD45.1 2D2-FIG SPL (150,000/well) 
were used as responders. CTV-labeled responders were cultured 
with CD45.2 2D2-FIG Tregs or with CD45.2 2D2-FIG Tcons 
(25,000/well) in the presence or absence of 1  µM MOG35-55 
and rat IL-2. After 5 days of culture, proliferation of CD45.1 2D2 
T cells was analyzed by measuring CTV dilution.
induction and assessment of eae
CFA (Incomplete Freund’s Adjuvant plus 4  mg/ml heat-killed 
Mycobacterium tuberculosis H37Ra, BD Biosciences, Franklin 
Lakes, NJ, USA) was mixed 1:1 with MOG35-55 in phosphate-
buffered saline. The CFA/antigen mixture was emulsified by 
sonication. EAE was elicited in B6 mice by injection of 100 or 
200  µg MOG35-55 in a total volume of 100  µl emulsion via 
three subcutaneous injections of 33  µl across the upper back. 
Each mouse received separate injections (200 ng i.p.) of Pertussis 
toxin on days 0 and 2. All immunizations were performed under 
isoflurane anesthesia (Abbott Laboratories, Chicago, IL, USA). 
Mice were assessed daily for clinical score and body weight. The 
following scale was used to score the clinical signs of EAE: 0, no 
disease; 0.5, partial paralysis of tail without ataxia; 1.0, flaccid 
paralysis of tail or ataxia but not both; 2.0, flaccid paralysis of 
tail with ataxia or impaired righting reflex; 3.0, partial hind limb 
paralysis marked by inability to walk upright but with ambulatory 
rhythm in both legs; 3.5, same as above but with full paralysis of 
one leg; 4.0, full hindlimb paralysis; 5.0, total hindlimb paralysis 
with forelimb involvement or moribund. A score of 5.0 was a 
humane endpoint for euthanasia.
The incidence of EAE reflected the number of mice afflicted 
with EAE compared to the total group size. Cumulative EAE 
scores were calculated by summing daily scores for each mouse 
across the time course of disease. Maximal scores were calculated 
as the most severe EAE score for each mouse. Mice that did not 
exhibit EAE had a score of 0 for the cumulative and maximal 
scores, and these scores were included in the group average. 
Mice that exhibited humane endpoints as assessed by body 
weight loss, body score, or clinical score of 5.0 were subjected 
to humane euthanasia and were omitted from scoring thereafter. 
Time-course graphs portrayed daily mean maximal scores. 
To calculate percent maximal weight loss, 100% body weight 
was assigned as the maximal body weight obtained from day 1 
through day 10, and daily body weights were calculated for each 
day after normalization to this 100% value. The minimum body 
weight was defined as the lowest body weight after normalization 
to the 100% value during the span of day 11 until the end of the 
experiment. Maximal weight loss was calculated by subtraction 
of the normalized minimum value from the 100% value. Average 
weight loss was calculated as the average of daily body weight 
measurements from day 11 until the end of the experiment, 
subtracted from the 100% maximal body weight.
statistical analysis
To determine statistical significance, comparisons among three or 
more groups were analyzed by use of ANOVA, and comparisons 
between two groups were analyzed by a Student’s t-test. A p-value 
<0.05 was considered significant. For EAE mean clinical scores 
and percent initial body weight, error bars represent SEM. For all 
other data, error bars represent SD.
resUlTs
The concept of a Treg Window
To optimize antigen-dependent induction of Tregs, designated 
concentrations of MOG35-55 were used to activate 2D2-FIG SPL 
in the presence of 10 nM TGF-β (Figure 1). 2D2-FIG T cells are 
specific for MOG35-55 and have an IRES-GFP reporter knock-in 
immediately downstream of the FOXP3 gene. The CD4+ T cell 
compartment of 2D2-FIG mice typically contained ≤1% FOXP3+ 
T cells at steady state. After 3 days, 320 nM or 1 µM MOG35-55 
elicited percentages of FOXP3+ Tregs (54 and 60%, respectively) 
that were significantly higher than the 40% Tregs induced 
by the higher concentrations of 3.2 and 10  µM MOG35-55 
(Figures 1A,C). Thus, the antigen-dependent induction of FOXP3 
resembled a bell-shaped curve. MOG-induced FOXP3 expression 
was entirely dependent upon TGF-β (25). The antigen-dependent 
expression of CD25 was at least twofold higher on Tregs than on 
Tcons, and this difference was maximal at intermediate antigen 
concentrations of MOG35-55 (320 nM–3.2 µM) (Figures 1B,D). 
Similar patterns were noted regarding the concentration depend-
ence of OVA323-339 for CD25 expression on OVA-specific 
OTII-FIG T  cells in the presence of TGF-β (Figures  1E,F). A 
lower range of OVA323-339 concentrations was optimal because 
OT-II T  cells have more potent antigenic responsiveness than 
2D2 T cells. These data confirm the prediction that activated 2D2 
and OT-II Tregs exhibit superior CD25 expression compared to 
Tcon subsets.
To realize the goal of achieving long-term stable growth 
of FOXP3+ Tregs, we reasoned that an anti-CD25 mAb would 
differentially block the IL-2-dependent growth and survival of 
Treg and Tcon subsets. High levels of CD25 were postulated to 
confer partial resistance to anti-CD25 mAbs among Tregs while 
completely blocking IL-2-dependent responses of Tcons. Based 
on this concept, we predicted that a “Treg window” could be 
operationally defined by adjusting the relative concentrations of 
FigUre 1 | Intermediate concentrations of antigen induced higher percentages of FOXP3+ regulatory T cells (Tregs). 2D2-FIG (a–D) or OTII-FIG (e,F) splenocytes were 
activated at a density of 2 × 106 cells/ml cRPMI in the presence of 10 nM TGF-β with the indicated concentration of MOG35-55 or OVA323-339. After 3 days, Vβ11+ 
(2D2) or Vβ5.1+ (OT-II) T cells were analyzed for expression of FOXP3 (a,c,e) and CD25 (B,D,F). Numbers at the bottom of each dotplot in panel (a) represent the 
percentages of FOXP3+ T cells, and the numbers in panel (B) represent the median fluorescence intensity of CD25 expression within the FOXP3− [conventional T cell 
(Tcon)] and FOXP3+ (Treg) populations. *p < 0.05, **p < 0.01, ***p < 0.001. These data are representative of three independent experiments.
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IL-2 and anti-CD25 mAb that would favor dominant survival and 
expansion of Tregs.
The anti-cD25 Pc61 mab stabilized 
short-term Treg cultures
To test whether an anti-CD25 antibody could be used to enrich Treg 
lines, 2D2-FIG SPL were activated with MOG35-55 (Figure 2A, 
top row), MOG35-55 and TGF-β (second row), or MOG35-55, 
TGF-β, and the anti-CD25 antibody PC61 (third row) for 3 days 
and then passaged into IL-2 containing media (without antigen or 
TGF-β) in the absence (rows 1 and 2) or presence (row 3) of PC61. 
In cultures of TGF-β-induced FOXP3+ Tregs (second row), Treg 
percentages gradually waned during subsequent propagation in 
IL-2 from a frequency of 47% on day 4 to 19% by day 13. Treg 
percentage values are given in the bottom right of each panel. 
In TGF-β-induced cultures that were continuously supplemented 
with 10 µg/ml (65 nM) of PC61 (bottom row), Treg differentiation 
was inhibited by PC61 during the initial 3-day activation culture. 
However, during the subsequent culture with PC61 and IL-2, 
the Treg frequency increased from 12% on day 4 to 86% by day 
13. The elevated Treg frequencies were associated with stronger 
GFPbright fluorescence which is a correlate of FOXP3 expression 
(values given at top of each panel). These data indicated that PC61 
enabled the selective enrichment of Tregs during propagation in 
IL-2 over 13 days of culture. Cultures seeded in the absence of 
TGF-β were used as a reference to gauge the GFP+ window. These 
data revealed that CD25 was important for the initial induction 
of Tregs, because PC61 inhibited FOXP3 differentiation in the 
initial 3-day activation. Conversely, partial blockade of the IL-2/
CD25 signaling pathway had the opposite activity in the IL-2 
propagation cultures, because PC61 was needed to maintain 
FOXP3+ Tregs during culture in IL-2. Overall, these data showed 
that PC61, when used to supplement IL-2 expansion cultures, 
selected FOXP3+ Tregs as the dominant lineage.
PC61 lacked cytotoxic activity in  vitro, although whether 
PC61 neutralized or down-modulated CD25 was uncertain. To 
assess this issue, 2D2-FIG SPL were activated for 3  days with 
1  µM MOG35-55 and 10  nM TGF-β and then were passaged 
every 3–4 days in IL-2 and 10 µg/ml PC61 (Figure 2B). Again, 
antigen and TGF-β were not included in the IL-2 expansion phase 
of these experiments. Analyses on days 11 and 17 revealed that 
the line was almost entirely comprised of FOXP3+ Tregs (>90%). 
A PE-conjugated 3C7 anti-CD25 mAb, which recognizes a site 
on CD25 distinct from the PC61 epitope, revealed high levels 
of CD25 on these Tregs despite the continuous culture in PC61 
and the saturation of CD25 with PC61 (Figure 2B, bottom pan-
els). Conversely, an APC-conjugated PC61 did not bind CD25 
FigUre 2 | The anti-CD25 PC61 monoclonal antibody (mAb) selectively favored regulatory T cell (Treg) dominance in mixed Treg/conventional T cell cultures. (a–D) 
2D2-FIG splenocytes were activated at a density of 2 × 106 cells/ml in cRPMI with MOG35-55 (1 µM) in the presence or absence of TGF-β (10 nM) and/or 
designated concentrations of PC61 (10 µg/ml; 65 nM, unless designated otherwise). Antigen and TGF-β were present only in the first activation culture and not 
thereafter. After 3–4 days of activation, cells were passaged at a density of 106 cells/ml in media containing rat IL-2 with or without PC61. Cultures initiated with 
PC61 were continued with PC61 during passage into the same conditions every 2–4 days. (a) Cells were analyzed on days 4, 6, 8, and 13 post-activation for 
FOXP3 expression by gating on Vβ11+ cells. The percentage of FOXP3+ Tregs compared to total Vβ11+ cells is indicated in the bottom right of each dotplot. The 
geometric mean fluorescence intensity of GFP expression is indicated at the top of each gate. (B) The initial T cell activation culture did not include PC61, and 
T cells were then passaged every 3–4 days in rat IL-2 and 10 µg/ml PC61. Vβ11-gated T cells were analyzed on day 11 and 17 for expression of CD25 by 
PE-conjugated 3C7 or APC-conjugated PC61 anti-CD25 mAb. (c,D) The initial activation culture with (c) or without (D) TGF-β included concentrations of PC61 
(10, 1, 0.1 µg/ml, or none) that were maintained throughout the course of the experiment. On days 3, 5, 7, and 9, Vβ11+ cells were analyzed for FOXP3 expression 
and for binding of an APC-conjugated anti-CD25 PC61 mAb. These data are representative of three independent experiments.
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because PC61-specific epitopes on CD25 were saturated with 
unlabeled PC61 mAb that had bound CD25 during the culture 
phase (Figure  2B, top panels). These data indicate that PC61 
facilitates Treg selection, at least in part, by functional neutraliza-
tion of CD25 in vitro.
An important question was whether Treg enrichment required 
PC61-mediated saturation of CD25 (Figure 2C). To assess this 
question, 2D2-FIG T cells were activated for 3 days with MOG35-
55 and TGF-β in the presence or absence of designated PC61 
concentrations. As noted before, high concentrations of PC61 
inhibited Treg induction when assessed on day 3. The T  cells 
were then passaged into IL-2 on day 3 with the same PC61 con-
centrations but without antigen or TGF-β. On days 5 through 9, 
concentrations of 1 and 10 µg/ml PC61 nearly saturated CD25 as 
determined by a lack of surface labeling by an APC-conjugated 
PC61 mAb (y-axis), because pre-existing PC61–CD25 complexes 
prevented the binding of APC-conjugated PC61. These PC61 
concentrations (1 and 10  µg/ml) respectively facilitated Treg 
enrichment to frequencies of 45 and 74%. PC61 dose dependently 
augmented GFP MFI (mean fluorescence intensity; four-digit 
number on the right of right-most column) on day 9 and thereby 
supported the hypothesis that PC61 preferentially selected 
mature Tregs. In the presence of 0.1 µg/ml PC61 or in control 
cultures without PC61, Tregs and Tcons expressed high levels of 
free CD25, and Treg frequencies were sparse at approximately 
20% throughout the 9  days of culture. Importantly, PC61 by 
itself did not induce FOXP3, as T cells activated without TGF-
β and cultured in the presence of PC61 did not result in Tregs 
FigUre 3 | PC61 allowed for rapid generation of pure regulatory T cell (Treg) lines. 2D2-FIG splenocytes (SPL) (a,B,D,e) or OTII-FIG SPL (c) were activated at a 
density of 2 × 106 cells/ml in cRPMI with MOG35-55 (1 µM) or 100 nM OVA323-339, respectively, with 10 nM TGF-β in the presence or absence of 10 µg/ml PC61. 
Antigen and TGF-β were present only in the initial 3-day activation culture and not thereafter. (a–c) PC61 was (PC61 at activation) or was not (PC61 after activation) 
included in the initial 3-day activation culture but was included in both groups after passage of the cells on day 3. Cells were counted and then analyzed to 
determine percentages of viable, Vβ11+ (2D2), Vβ5.1+ (OTII), FOXP3+ T cells on the designated days. (B) Shown are the 2D2-FIG Treg yields on days 3 and 5. (D,e) 
After 3 days of activation with or without PC61, 2D2-FIG T cells were passaged for 10 days at a density of 106 cells/ml in rat IL-2 in the presence or absence of 
10 µg/ml PC61. Cells gated as Vβ11+ FOXP3+ Tregs or FOXP3− conventional T cells (Tcons) were analyzed for expression of latency-associated peptide (LAP), 
GARP, GITR, and PD-1 on day 10 post-activation. MFI Values were normalized so that values obtained from T cells cultured in the absence of PC61 was equal to 1. 
These experiments are representative of three independent experiments.
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(Figure 2D). These data indicate that TGF-β-iTregs continuously 
required saturating PC61 concentrations during propagation in 
IL-2 to engender high percentages of Tregs.
Although PC61 stabilized Tregs in IL-2 maintenance cultures, 
inclusion of PC61 in the initial 3-day activation culture appeared 
to delay Treg induction. To assess this issue, PC61 was or was 
not included in the initial 3-day activation culture together with 
2D2-FIG SPL, MOG35-55, and TGF-β (Figure  3A), and then 
PC61 was included in the IL-2 maintenance cultures of both 
groups through day 9. Regardless of whether PC61 was added on 
day 0 (PC61 at activation) or day 3 (PC61 after activation), PC61 
facilitated the emergence of highly enriched FOXP3+ Tregs by 
day 9. However, introduction of PC61 after the initial activation 
culture was advantageous because this regimen resulted in the 
accelerated enrichment of Tregs as noted by differences at days 
3–5 (Figure 3A) and increased Treg yields at day 5 (Figure 3B). 
Treg yield on day 5 post-activation was more than sevenfold 
higher in the “PC61 after activation” group compared to “PC61 
at activation” group. Cultures that lacked PC61 in both phases 
of culture (No PC61) resulted in a dramatic reduction in Treg 
percentages but similar cell yields compared to the “PC61 after 
activation” group. Interestingly, PC61 was necessary at activation 
and during propagation to generate highly pure, stable OT-II 
Treg lines (Figure 3C). This phenomenon is most likely due to 
the high responsiveness of OT-II T cells to their cognate antigen 
(OVA323-339). That is, PC61-mediated inhibition was needed 
earlier in the activation cascade due to the higher antigen reac-
tivity of OT-II T cells. Thus, the requirement for the anti-CD25 
mAb during the initial culture for OTII-FIG T cells may reflect 
the antigenic potency of the cognate antigen. Nevertheless, 2D2 
and OT-II FOXP3+ enriched lines were obtained without physical 
purification or any genetic modification by the end of the experi-
ment. These findings indicated that the presence of PC61 during 
the IL-2 expansion phase was critical for achieving high Treg 
percentages in stable FOXP3+ Treg lines.
To assess whether PC61 affected expression of selected Treg 
markers, 2D2-FIG SPL were subjected to a 3-day activation 
with MOG35-55 and TGF-β (Figures  3D,E). The T  cells were 
then passaged every 3–4 days in IL-2 for an additional 10 days 
in the presence or absence of PC61, whereby the lines were 
almost exclusively small, rested T  cells. Gated Treg and Tcon 
subsets were analyzed separately. PC61-cultivated Tregs differed 
FigUre 4 | PC61 enabled the preferential outgrowth of TGF-β-induced iTregs from 2D2-FIG Rag1−/− mice. 2D2-FIG Rag1−/− mice splenocytes were activated for 
4 days at a density of 2 × 106 cells/ml in cRPMI with MOG35-55 in the presence or absence of 1 nM TGF-β to generate regulatory T cells (Tregs) and conventional 
T cells, respectively, and were passaged at a density of 5 × 105 cells/ml in cRPMI with rat IL-2 on day 0 of the rest phase. T cells were then passaged with or 
without PC61 (10 µg/ml) (in the absence of TGF-β and MOG) as designated every 2–4 days. Vβ11+ T cells were assessed for FOXP3 expression on days 0, 4, 7, 
and 10 after activation. Shown are representative dot plots of the percentage of FOXP3+ Tregs in the Vβ11+ T cell population (a) and the corresponding averages of 
triplicate samples (B). The bar graph shows the geometric MFI of FOXP3 expression in the FOXP3+ gate (c). The geometric mean fluorescence intensity was 
normalized so that the FOXP3 MFI of Tregs activated in the absence of TGF-β was equal to 1. *p < 0.05, **p < 0.01, ***p < 0.001. These experiments are 
representative of three independent experiments.
8
Wilkinson et al.  CD25 Antagonism Enables Treg Dominance
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1782
from control (no PC61) cultures via higher Treg expression of 
FOXP3, LAP, GARP, GITR, and PD-1. These data revealed that 
PC61-maintained Tregs had markers consistent with the Treg 
lineage and expressed significantly higher levels of these markers 
compared to Tregs cultivated in the absence of PC61, signifying 
the ability of PC61 to select mature Tregs.
An important question was whether iTregs that were 
induced de novo during activation in the presence of TGF-β 
were stabilized by PC61, because iTregs may be important start-
ing material for derivation of antigen-specific Tregs. Previous 
experiments however were initiated with total 2D2-FIG SPL, 
which may include pre-existing thymically derived tTregs that 
may contribute or dominate growth in the presence of PC61. In 
2D2-FIG mice, pre-existing Tregs typically comprise less than 
1% of CD4+ T cells, with a frequency range of approximately 
0.2–1.5% pre-existing FOXP3+ Tregs. To assess this issue, 
Tregs were induced with MOG and TGF-β from 2D2-FIG 
Rag1−/− mice, which lack tTregs (Figure  4). 2D2-FIG Rag1−/− 
Tregs were cultured in the presence of IL-2 with or without 
PC61. Tregs cultured in the presence of PC61 showed a stable, 
high percentage of Tregs (>75%), whereas Tregs cultured in 
the absence of PC61 showed a diminishing Treg percentage 
throughout the duration of the experiment (Figures 4A,B). The 
FOXP3 geometric mean fluorescence intensity (gMFI) of Tregs 
cultured in the presence of PC61 was significantly higher than 
the gMFI of Tregs cultured in the absence of PC61 (Figure 4C). 
These data provide evidence that PC61 stabilizes outgrowth of 
TGF-β-induced iTregs.
Pc61 Was the anti-cD25 mab of choice 
for Blockade of il-2 signaling and 
selection of Tregs
Because anti-CD25 mAbs differ in epitope specificity and inhibi-
tory mechanism, three anti-CD25 mAb were screened for inhibi-
tory efficacy in assays of IL-2-dependent T cell growth. The PC61 
mAb (rat IgG1, λ) was more suppressive than the 7D4 mAb (rat 
IgM, κ), whereas the 3C7 mAb (rat IgG2b, κ) lacked inhibitory 
activity at this concentration of IL-2 (Figure 5A). PC61 may have 
superior efficacy because PC61 and IL-2 bind distinct sites on the 
CD25 IL-2Rα, and PC61 facilitates the dissociation of IL-2, but 
not vice versa (31). Although PC61 is routinely used for depletion 
of Tregs in vivo (27), the PC61 mAb had no cytolytic or depleting 
activity in vitro, as shown previously in Figure 2. PC61 mediates 
Treg depletion in vivo via FcγR-mediated clearance (27), but this 
mechanism was not operational in T cell cultures.
As shown in Figure 5B, PC61 and IL-2 exhibited functional 
competition in cultures of a transformed Tcon line that expressed 
a CD25high phenotype and potent IL-2 responsiveness. High 
concentrations of PC61 (up to 1 µM) inhibited IL-2 responses in 
the presence of limiting IL-2 concentrations (<10 nM) as shown 
by right-shifted IL-2 concentration–response curves. In contrast, 
high concentrations of IL-2 (≥10 nM) overwhelmed the inhibitory 
action of all tested concentrations of PC61. High concentrations 
of IL-2 may signal through lower affinity IL2Rβ–γ complexes 
and thereby may drive IL-2 dependent growth independent of 
CD25. Overall, these data indicate that PC61 effectively inhibited 
FigUre 5 | The PC61 anti-CD25 monoclonal antibody (mAb) was a functional antagonist of IL-2 growth at low concentrations of IL-2 and was superior to the 7D4 
and 3C7 anti-CD25 mAbs for maintenance of regulatory T cells. (a,B) A continuously propagated line of IL-2 dependent CD4+ T cells (SJL-PLP.1 T cells) was used 
as IL-2 responders in these assays. These T cells (3,000/well) were cultured with rat IL-2 and designated concentrations of PC61, 7D4, or 3C7 mAbs (a) or were 
cultured with designated concentrations of purified PC61 and mouse IL-2 (B). Cells were pulsed with [3H]thymidine during the last 24 h of a 3-day culture.  
(c) 2D2-FIG splenocytes were activated at a density of 2 × 106 cells/ml cRPMI with 1 µM MOG35-55 in the presence of 10 nM TGF-β. After 3 days, cells were 
passaged at a density of 106 cells/ml with IL-2 plus 10 µg/ml PC61, 7D4, 3C7, or no anti-CD25 mAb. Cells were passaged every 3–4 days in IL-2 with the same 
anti-CD25 antibody. Vβ11+ T cells were analyzed for FOXP3 expression on days 10, 15, and 22. These experiments are representative of three independent 
experiments.
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IL-2 responses, but only within a range of relatively low IL-2 
concentrations.
As predicted based on its superior IL-2 inhibitory activity 
(Figure 5A), PC61 was more efficient than the anti-CD25 mAb 
7D4 and 3C7 for maintenance of Treg cultures (Figure 5C). Due 
to the superior inhibitory efficacy and superior Treg selectivity, 
the anti-CD25 PC61 mAb was used for the remainder of the study.
Pc61 enabled the Dominant Outgrowth of 
Tregs in Mixed Treg/Tcon cultures
The concept of a Treg window was tested with mixed 2D2 
(MOG-specific) lines of FOXP3+ and FOXP3− T cells (Figure 6). 
These T cells were propagated in IL-2 for 16 days before use in 
this assay, so that Tregs represented nearly 96% of the T  cells 
in the FOXP3+ line. Equal numbers of Tcons and Tregs were 
labeled with CellTrace Violet (CTV) and were cultured for 6 days 
with designated concentrations of IL-2 and PC61. This analysis 
distinguished proliferative subsets (left quadrants) from non-
proliferative subsets (right quadrants) as well as Tregs (upper 
quadrants) from Tcons (lower quadrants) (Figure  6A). Shown 
are two relatively low IL-2 concentrations (100 and 316 pM) in 
which proliferative and non-proliferative Tregs were dominant 
(exhibited higher percentages) compared to Tcons when cultured 
with 1 µM PC61. At 100 pM IL-2 and either 1 µM PC61 or “no 
PC61,” 78 or 45% of T cells (sum of upper two quadrants) were 
Tregs, respectively. At 316 pM IL-2, proliferative Tregs exhibited 
higher frequencies than proliferative Tcons in the presence but 
not absence of 10 nM, 100 nM, and 1 µM PC61. At high IL-2 
concentrations (e.g., 10 nM), Tcons were dominant and showed 
overgrowth regardless of PC61 concentration. The concentration-
dependent ability of PC61 to promote Treg dominance in low 
IL-2 concentrations (Figure 6B) correlated with preservation of 
high GFP fluorescence (Figure 6C), which is an indirect measure 
of FOXP3 expression on a per cell basis. Tregs were dominant 
within a 10-fold range of IL-2 concentrations (320 pM–3.2 nM, 
Figure 6D) in the presence of 1 µM PC61, whereas Tcons were 
dominant at the same IL-2 concentrations in the absence of PC61. 
Although PC61 exhibited concentration-dependent inhibition of 
IL-2-dependent Treg growth, PC61 was a more potent inhibitor 
of Tcon growth at limiting IL-2 concentrations, such that dif-
ferential growth and survival favored persistence of Tregs over 
Tcons (Figure 6E). Overall, these data reveal a “Treg window” 
defined by ranges of IL-2 and PC61 concentrations that enabled 
dominant survival and outgrowth of FOXP3+ Tregs.
The anti-cD25 Pc61 antibody enabled 
Maintenance of long-term lines of 
FOXP3+ Tregs
Given that PC61 was instrumental in selecting enriched FOXP3+ 
Treg lines over a 2- to 3-week timespan (Figure  2), a critical 
question was whether PC61 also allowed maintenance of highly 
enriched Treg lines over the course of months. To assess this ques-
tion, 2D2-FIG SPL were activated with MOG35-55 and TGF-β in 
a 3-day activation in the absence of PC61 and were then passaged 
every 3–4 days in IL-2 with 10 µg/ml PC61 (Figure 7A). Over 
the course of 68 days, the line was analyzed for percentages of 
FigUre 6 | Continued
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FOXP3+ Tregs. Tregs represented over 90% of the cells by day 15 
and persisted at these levels throughout the duration of the cul-
ture without showing any signs of attenuation. Equivalent lines 
propagated in IL-2 but in the absence of PC61 showed progressive 
loss and extinction of FOXP3+ Tregs across 2–4 weeks of propaga-
tion in IL-2 (e.g., Figure 2).
FigUre 6 | Continued  
A permissive “Treg window” that favored dominance of FOXP3+ regulatory T cells (Tregs) was defined by low IL-2 concentrations and high PC61 concentrations. 
2D2-FIG T cells were cultured with 1 µM MOG35-55 for 4 days in the presence or absence of 10 nM TGF-β to establish lines of FOXP3+ Tregs and FOXP3− 
conventional T cells (Tcons), respectively. T cells were passaged every 3 or 4 days for a total 16 days in IL-2, and Treg cultures were also supplemented with 10 µg/
ml PC61 to select and establish high percentages of FOXP3+ Tregs. At the initiation of the experiment, Tregs and Tcons were equally mixed and labeled with CTV 
and were cultured for 6 days in designated concentrations of IL-2 (100 pM–10 nM) in the presence or absence of designated concentrations of PC61. Dotplots in 
panel (a) show proliferating (left quadrants) versus non-proliferating (right quadrants) Tregs (top quadrants) and Tcons (bottom quadrants). Shown are percentages 
(B) and MFI (c) of FOXP3+ Tregs in the Vβ11+ population. (D) Shown are the percentages of proliferating FOXP3+ Tregs and FOXP3− Tcons in the presence or 
absence of 1 µM PC61. (e) Normalized proliferation of Tregs and Tcons at designated concentrations of IL-2 and PC61. This experiment is representative of three 
independent experiments.
FigUre 7 | The anti-CD25 monoclonal antibody PC61 enabled long-term, stable propagation of FOXP3+ regulatory T cells (Tregs). 2D2-FIG splenocytes (SPL) or 
FIG SPL were activated with 1 µM MOG35-55 or 2.5 µg/ml Con-A, respectively, at a density of 2 × 106 SPL/ml in the presence of 10 nM TGF-β. After 3 days of 
activation, cells were passaged at a density of 106 cells/ml in media containing rat IL-2 and 10 µg/ml PC61. Cells were passaged every 3–4 days in the same 
conditions for the indicated durations. In 2D2-FIG cultures, Vβ11+ cells were analyzed on the indicated days for FOXP3 expression (a), Neuropilin-1 expression (c), 
and Helios expression (e,g). Panels (a,c) represent analyses of lines established from separate mice. (B,D,F) In C57BL/6 (B6)-FIG cultures, CD4+ T cells were 
purified to remove CD8+ T cells. FIG lines were analyzed for FOXP3 expression (B), Neuropilin expression (D), and Helios expression (F). For panels (e,F), Helios 
expression was measured in the FOXP3+ and the FOXP3− populations from the same line. These experiments are representative of three independent experiments.
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FOXP3+ Treg lines from naïve, clonotypically diverse FIG SPL 
could also be derived by addition of PC61 to IL-2 expansion cul-
tures (Figure 7B). Naïve FIG SPL were activated for 3 days with 
Con-A and TGF-β and then were propagated in IL-2 in the pres-
ence of PC61. CD4+ T cells were purified to remove CD8+ T cells 
in polyclonal FIG SPL cultures to prevent CD8+ T cell overgrowth 
of the line, but CD4+ T  cell purification was not necessary for 
2D2-FIG Tregs given that 2D2-FIG mice largely lacked CD8+ 
T cells. Over the course of 105 days, cultures became progres-
sively enriched with polyclonal FOXP3+ Treg cells until over 90% 
of the line was comprised of FOXP3+ Tregs. In subsequent poly-
clonal FIG Treg lines, CD4 purification was performed on day 4 
post-activation as opposed to day 10. This earlier intervention 
allowed for the generation of Treg lines consisting of >90% Tregs 
by day 10 (not shown). Culture of Treg lines in IL-2 expansion 
cultures with PC61 resulted in a slow and steady expansion of 
cell numbers. These findings reveal the generalized applicability 
of PC61-mediated Treg selection in mice. The implication is 
that Treg lines can be generated and maintained indefinitely in 
the presence of PC61. We have generated at least 15 different 
2D2-FIG Treg lines, 5 different OT-II Treg lines, and 4 different 
polyclonal Treg lines and carried them for more than 50  days 
with Treg percentages greater than 85% of the T cell population. 
Overall, these lines showed no loss of Treg percentages and no 
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decrement in GFP fluorescence (i.e., FOXP3 expression) over the 
entire culture duration.
These long-term lines expressed Neuropilin-1 and Helios, 
which have been associated with the FOXP3+ Treg phenotype 
(Figures 7C–G). Neuropilin-1 was expressed on both 2D2-FIG 
Tregs (Figure 7C) and polyclonal Tregs (Figure 7D). Neuropilin-1 
exhibited progressive increases in MFI as a function of time such 
that Neuropilin-1 expression was positively correlated with the 
longevity of culture. Given that Helios is a transcription factor 
implicated in Treg function, we also analyzed 2D2-FIG Tregs on 
day 60 of culture (Figure 7E) and polyclonal Tregs on day 66 of 
culture (Figure 7F) for expression of Helios. 2D2-FIG Tregs and 
polyclonal Tregs both expressed Helios, whereas Tcons lacked 
detectable expression. Like Neuropilin-1, Helios expression levels 
correlated with the duration of culture (Figure 7G). These find-
ings provided evidence that expression of both Neuropilin-1 and 
Helios was amplified by continuous, low-intensity IL-2 signaling 
in continuity with Treg lineage commitment.
reactivation and expansion of FOXP3+ 
Treg lines
We assumed that reactivation of FOXP3+ Treg lines would be 
a necessity for Treg-mediated suppressive activity in adoptive 
transfer experiments. The critical issue was whether FOXP3+ 
Tregs could undergo secondary activation in vitro without loss of 
FOXP3 and the Treg phenotype. Like the primary activation, we 
hypothesized that reactivation of established Treg lines would be 
contingent on TGF-β. To assess this issue, a 2D2-FIG line (>90% 
FOXP3+ Tregs) that had been cultured for 23 days in IL-2 and PC61 
was reactivated for 3 or 6 days with irradiated splenic APC and 
MOG35-55 in the presence of IL-2 with or without PC61 and the 
neutralizing anti-TGF-β 1D11 mAb (Figures 8A–C). The presence 
of PC61 during secondary activation stabilized Treg percentages 
at approximately 90% (Figure 8A top row; Figure 8B). The pres-
ence of PC61 also stabilized FOXP3 expression, as reflected by 
GFP MFI (Figure 8C). Notably, 1D11-mediated neutralization of 
TGF-β resulted in a loss of FOXP3+ Treg percentages to less than 
50% and a decrement in FOXP3 expression on a per cell basis, as 
reflected by the GFP MFI (Figure 8A middle row; Figure 8C). 
These data indicate that FOXP3 expression during antigen-driven 
cellular activation was maintained by TGF-β produced by cells in 
the culture.
These data provided evidence that exogenous TGF-β might 
augment Treg stability in subsequent reactivation cultures. To 
assess this issue, designated cell densities were used at a constant 
10:1 APC:Treg ratio at 4  ×  105 Tregs/ml, 2  ×  105 Tregs/ml, or 
105 Tregs/ml (Figure 8D; Table 1). In the absence of exogenous 
TGF-β, T  cells underwent activation and expansion at each 
density (Table 1), but Treg percentages declined, particularly at 
higher cell densities. Most likely, high T cell densities caused a 
more robust activation and perhaps enhanced the production 
of pro-inflammatory cytokines (i.e., IL-23 or GM-CSF) that 
might antagonize the action of TGF-β. Notably, the presence 
of exogenous TGF-β prevented decrement of Treg frequencies 
and stabilized the Treg phenotype regardless of the cell density. 
Based on cell counts, high initial cell densities in the presence of 
TGF-β enabled the most robust expansion of Tregs by day 3 of 
activation (Table 1). These data indicate that optimal Treg expan-
sion requires the presence of exogenous TGF-β during secondary 
activation. This observation is key to strategies for expansion of 
continuous FOXP3+ Treg lines.
To quantitate Treg expansion, an established, long-term 
2D2-FIG Treg line was activated for 3 days with irradiated bone 
marrow-derived dendritic cells, 2.5 µg/ml Con-A, 1 nM TGF-β, 
and IL-2 (Figures 8E,F). T cells were then passaged on days 3 
and 6 at a density of 5 × 105 cells/ml cRPMI containing rat IL-2 
with or without PC61. Viable cells were enumerated (Trypan Blue 
dye exclusion) and analyzed for Vβ11 and FOXP3 expression to 
calculate expansion of viable FOXP3+ Tregs. During the antigenic 
activation (days 0–3), Tregs expanded ~7-fold while retaining 
high FOXP3 expression in nearly 100% of the population. Tregs 
expanded another ~4-fold from days 3 to 6 for a net 26- to 28-fold 
expansion since day 0 (Figure  8F). Importantly, there was no 
difference in the expansion rates between Tregs cultured in the 
presence or absence of PC61 immediately following antigenic 
activation, such that CD25high Tregs were resistant to PC61 
antagonism. From days 6 to 9, Tregs reverted to a quiescent rest-
ing phase and did not expand in numbers either with or without 
PC61. The percentage of FOXP3+ Tregs in each culture remained 
>98% through the 6 days of IL-2 propagation regardless of the 
presence or absence of PC61. Overall, in long-term cultures of 
resting quiescent Tregs (i.e., weeks to months without activa-
tion), cell numbers were static or modestly expanded (onefold to 
twofold) over the course of a week. These data provide evidence 
that 2D2 Tregs can undergo an approximate 26-fold expansion 
over the course of 9  days following a 3-day cellular activation 
and 6 days of rest. This activation–rest strategy is based on the 
classical method for derivation of T cell lines and is also sufficient 
for expansion of stable FOXP3+ Treg lines.
Although PC61 was deleterious in the initial activation culture 
(Figure 2A), PC61 was beneficial in the secondary reactivation 
cultures (Figure  8). However, this difference reflected a differ-
ence of strategy regarding the initial selection of the line versus 
the subsequent reactivation and expansion of the line. That is, 
exogenous IL-2 was not added to primary activations to reinforce 
antigen specificity of the initial activation, whereas optimization 
experiments showed that the inclusion of exogenous IL-2 in 
secondary reactivation promoted expansion of the established 
clonotypic line. Basically, PC61 preserved the FOXP3 phenotype 
whenever exogenous IL-2 was added to the culture because 
unmitigated IL-2 signaling resulted in Tcon dominance and over-
growth/destabilization of the Treg line. Thus, PC61 was beneficial 
in secondary reactivation cultures because these cultures were 
supplemented with exogenous IL-2.
cultured Tregs exhibited In Vitro and 
In Vivo suppressive activities
Phenotypic analysis of activated Tregs revealed the activation-
dependent upregulation of functional Treg markers including 
LAP, CTLA4, GARP, and TIGIT (Figure  9). These data reveal 
that TGF-β-conditioned activation of Tregs upregulates several 
markers associated with suppressive Treg function. To determine 
if continuously propagated FOXP3+ Tregs have suppressive capa-
bilities, 2D2 Tregs were assayed for in vitro and in vivo suppressive 
FigUre 8 | Continued
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activity. To assess in vitro suppressive activity, CD45.2 2D2 Tregs 
were cultured for either 40 or 13 days in IL-2 and PC61, whereas a 
control CD45.2 2D2 Tcon line was derived by propagation in IL-2 
alone for 13 days. These Treg and control lines were then cultured 
with CTV-stained naïve responders from CD45.1 2D2 splenic 
leukocytes in the presence of MOG and IL-2 (Figure 10A). CTV 
TaBle 1 | Regulatory T cells (Tregs) exhibit stable expansion in the presence of 
exogenous TGF-β, IL-2, and PC61.
groupa aPc: Treg 















20:2 9.58 3.40 1.7 35
10:1 3.33 1.44 1.4 42
5:0.5 2.20 1.48 3.0 66
TGF-β 20:2 13.36 13.13 6.6 98
10:1 5.26 5.18 5.2 98
5:0.5 2.16 2.13 4.3 99
aT cells were rested for 33 days and were 94% FOXP3+ Tregs at the initiation of the 
experiment. T cells were activated with irradiated splenocytes (SPL), 1 µM MOG35-
55, rat IL-2, and 10 µg/ml PC61 and in the presence or absence of 100 pM TGF-β. 
Cultures were setup in 5 ml media containing designated numbers of Tregs and 
irradiated SPL (column 2).
bCells were analyzed on day 3 of activation by gating on Vβ11 and FOXP3 (GFP). 
Absolute cell counts (Trypan Blue exclusion), Vβ11+ T cell percentages, and FOXP3+ 
Treg percentages were used to calculate Treg numbers. Treg yield was calculated by 
dividing the Treg cell count on day 3 by the starting Treg count (2 × 106, 1 × 106, or 
0.5 × 106) on day 0. These data are representative of three independent experiments.
FigUre 8 | Continued  
TGF-β was required for the maintenance of regulatory T cell (Treg) stability during secondary Treg activation and expansion. (a–c) 100,000 Tregs (rested for 23 days, 
93% FOXP3+) and 106 irradiated splenic APC were cultured in 200 µl with 1 µM MOG35-55 and IL-2 with or without 10 µg/ml PC61 and the 1D11 anti-TGF-β 
monoclonal antibody (50 µg/ml) as designated. Cells were analyzed on days 3 and 6 of activation. (a) FOXP3+ Treg percentages are shown in bottom right corner 
for the Vβ11+ 2D2 TCR-gated population. Also shown are the average percentages of FOXP3+ Tregs per Vβ11+ T cells (B) and average FOXP3 (GFP) MFI (c). Error 
bars represent SDs. *p < 0.05, **p ≤ 0.01, ***p ≤ 0.001. (D) Tregs that were rested for 33 days (94% FOXP3+) were reactivated with irradiated splenocytes (SPL) 
and 1 µM MOG35-55 in the presence of 10 µg/ml PC61 with (bottom row) or without (top row) 100 pM TGF-β. Activation cultures contained rat IL-2 with designated 
densities of Tregs and irradiated splenic APC in 5 ml media as indicated above each set of dotplots. For example, 20 × 106 irradiated SPL were used to activate 
2 × 106 Tregs. Alternatively, 10 × 106 or 5 × 106 APC were used to activate 106 or 5 × 105 Tregs, respectively, in a 5-ml volume. Cells were analyzed on days 3 and 6 
of activation by gating on Vβ11+ T cells. Percentages of FOXP3+ cells are shown in the top right corner of each dotplot. (e,F) 250,000 2D2 induced-Tregs were 
induced by culturing FACS-sorted naïve FOXP3null T cells with 50,000 irradiated bone marrow-derived dendritic cells, 2.5 µg/ml Con-A, IL-2, and 1 nM TGF-β. T cells 
were passaged into IL-2 with or without 10 µg/ml PC61 on day 3 and were subsequently passaged again on day 6 at a density of 5 × 105 cells/ml. Cells were 
counted by Trypan Blue exclusion and analyzed by flow cytometry for FOXP3 expression on Vβ11+ gated T cells. Cell yields (F) were calculated by multiplying cell 
counts by the percentage of Vβ11+ FOXP3+ cells on days 3, 6, and 9. These experiments are representative of three independent experiments.
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dilution was measured in the CD45.1+ responders after 5 days as 
a measure of T cell proliferation. Suppressive activity was based 
on the percentages of hypo-proliferative CD45.1 2D2 T  cells 
(Figure  10B). Responder 2D2 T  cell proliferation was signifi-
cantly inhibited by the presence of 2D2 Tregs when compared to 
cultures containing the 2D2 Tcon line. There was no difference in 
suppressive activities of Tregs rested for 40 or 13 days. These data 
provide evidence that Treg function is maintained when Tregs are 
continuously cultured with IL-2 and PC61.
A central question was whether these Tregs, representing the 
2D2 MOG35-55-specific clonotype, exhibited suppressive activ-
ity in adoptive transfer experiments. To address this question, a 
continuous line of FOXP3+ Tregs was activated with irradiated 
splenic APC, 1  µM MOG35-55, IL-2, and 100  pM TGF-β for 
3 days but without PC61 mAb to avoid coating the T cells with 
a rat IgG1 mAb that had depleting activity in vivo. Cell-surface 
PC61 remained high in the immediate aftermath of the activation 
culture, and thus the Tregs were cultured overnight in IL-2 to 
remove more cell-surface CD25/PC61 complexes. Phenotypic 
analysis of Tregs on the day of transfer showed that 93% were 
FOXP3+ CD25high Tregs (Figure  10C). Most of the transferred 
Tregs had no or low detectable levels of PC61 on the cell 
surface as determined by staining with anti-rat IgG secondary 
antibody (Figure  10D). 65% of Tregs were CD44highCD62Lhigh, 
whereas 33% of Tregs were CD44high CD62Llow (Figure  10E). 
One day after adoptive transfer, mice were actively challenged 
to elicit EAE. The adoptive transfer of Tregs ameliorated sever-
ity of clinical paralysis and EAE-associated loss of body weight 
(Figures 10F,G). Recipients of Tregs (n = 6) differed from con-
trol mice (n = 5) in mean cumulative scores (12.2 ± 4.0 versus 
26.8 ± 4.6; p = 0.0198), mean maximal scores (2.0 ± 0.7 versus 
3.6  ±  0.2; p  =  0.0343), mean maximal weight loss (12.5  ±  4.4 
versus 28.7 ± 1.1%; p = 0.00475), and mean average weight loss 
(5.7 ± 3.3 versus 21.5 ± 2.4%; p = 0.00249). Mice that received 
Tregs had significantly lower mean daily clinical EAE scores on 
days 9–13 and 15–21 and significantly less weight loss on days 
11–20 as assessed by the Student’s t-test. These data provided 
evidence that PC61 enables the selection of immunosuppressive 
FOXP3+ CD25high Tregs that when appropriately activated have 
the ability to inhibit EAE in adoptive transfer experiments.
To address the Treg adoptive immunotherapy in a relevant 
preclinical model, adoptive transfer of activated FOXP3+ Tregs 
was performed in mice that were exhibiting severe paralytic EAE 
(Figures 10H,I). Mice were actively challenged with MOG35-55 
in CFA to induce EAE on day 0 and then were separated into two 
groups that were matched for EAE severity and weight loss on day 
15. Blastogenic FOXP3+ Tregs were previously prepared by acti-
vation for 3 days with irradiated bone marrow-derived dendritic 
cells, Con-A, MOG35-55, IL-2, Vitamin C, and TGF-β. These 
activation cultures were supplemented with Vitamin C due to the 
emerging awareness that the vitamin acts to promote functional-
ity and stability to effector Tregs (32–36). Approximately 97% 
of cells expressed high levels of FOXP3, and these blastogenic 
Tregs had low to no detectable PC61. Adoptive transfer of these 
Tregs significantly alleviated severity of EAE based on a decrease 
in mean clinical score and an increase in body weight. When 
analyzed from days 20 to 28, mice that received Tregs (n =  4) 
differed from control mice (n  =  5) in mean cumulative scores 
(13.3 ± 3.3 versus 28.4 ± 1.7; p = 0.003), mean maximal scores 
(2.1 ± 0.5 versus 3.8 ± 0.2; p = 0.0035), mean maximal weight loss 
(19.7 ± 0.9 versus 27.3 ± 2.2%; p = 0.0103), and mean average 
weight loss (12.7  ±  0.9 versus 22.8  ±  1.7%; p  =  0.00102). The 
transfer of Tregs significantly alleviated the severity of EAE based 
on a decrease in mean daily clinical scores from days 18 to 28 
FigUre 9 | Reactivated regulatory T cells (Tregs) upregulated Treg-associated activation markers. To generate activated Tregs, 100,000 rested Tregs (>90% 
FOXP3+) and 106 irradiated splenocytes were cultured for 2 days with 1 µM MOG35-55, rat IL-2, and 10 µg/ml PC61. A control rested Treg line was passaged in 
IL-2 and PC61. Activated Tregs versus rested FOXP3+ Tregs were gated and analyzed for the indicated markers. Representative overlapping histograms are shown 
in panel (a). Relative MFIs for the indicated markers on gated Tregs are shown in panel (B). MFI values were normalized so that rested Treg MFI values were equal to 
1. ***p < 0.001. These data are representative of three independent experiments.
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and an increase in body weight from days 22 to 28. These data 
provided evidence that blastogenic 2D2 Tregs can mitigate EAE 
when administered in a therapeutic treatment regimen.
like the Bivalent Pc61 mab, a Monovalent 
Pc61scFv Promoted the Dominant 
Outgrowth of FOXP3+ Tregs in Mixed 
cultures
We derived an expression system for a single-chain fragment 
variable (scFv) version of PC61 to assess whether a monovalent 
non-signaling version of PC61 retained Treg-stabilizing ability. 
This PC61scFv protein has the same binding specificity as PC61 
(anti-CD25). However, unlike the intact PC61 mAb, PC61scFv 
was monovalent and therefore lacked cross-linking activity nec-
essary for signaling. The PC61scFv also lacked constant region 
heavy chain domains and therefore lacked interactions with 
complement and FcγR. The PC61scFv is predicted to have quali-
tative advantages over intact PC61 in regard to tissue penetrance 
and absence of in  vivo depleting activity. We tested the ability 
of this monomeric PC61scFv to stabilize Tregs in short-term 
cultures in comparison to the PC61 mAb (Figure 11). 2D2-FIG 
Tregs were activated with MOG35-55 in the presence of TGF-
β for 3 days before being passaged into media containing IL-2 
along with 65 nM PC61scFv, 65 nM PC61 mAb, or vehicle. Cells 
were passaged under the same conditions every 3–4  days. The 
presence of PC61scFv resulted in high Treg percentages (85% on 
day 14) indicating that PC61scFv mimicked the effect of PC61 
mAb in vitro (Figures 11A,B). PC61scFv was slightly less efficient 
compared to the intact PC61 mAb, although this minor difference 
most likely was due to the lower affinity associated with mono-
valent binding, in contrast to the bivalent interactions of intact 
PC61 with CD25. The specificity of PC61scFv was confirmed 
by the ability of surface-bound PC61scFv to block the binding 
of a fluorochrome-conjugated PC61 mAb (Figure  11C). These 
data indicate that PC61 mediates Treg stabilization via CD25 
neutralization rather than CD25 cross-linking.
DiscUssiOn
Stable growth of autoreactive, TGF-β-induced FOXP3+ Tregs 
represents a critical prerequisite for effective Treg adoptive 
immunotherapies of autoimmunity and chronic inflammatory 
disease. However, the lack of viable strategies to maintain and 
expand functional CD25high FOXP3+ Tregs in sustained culture 
has severely limited progress. Solutions to this problem represent 
a critical unmet need. The main issue is that FOXP3 expression in 
some Tregs wanes on a per cell basis over time, and otherwise sta-
ble FOXP3+ Tregs are overgrown by Tcons when cultured in IL-2, 
FigUre 10 | Continued
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FigUre 11 | Like the intact PC61 monoclonal antibody (mAb), the monovalent PC61scFv stabilized regulatory T cell (Treg) lines. 2D2-FIG splenocytes were 
activated at a density of 2 × 106 cells/ml in cRPMI with MOG35-55 (1 µM) in the presence of TGF-β (10 nM). After 3 days of activation, T cells were cultured (n = 2) 
at a density of 500,000 cells/ml in IL-2 together with 65 nM PC61scFv, 65 nM PC61 mAb, or vehicle. Cells were passaged under the same conditions every 
3–4 days. (a,B) Representative dotplots and timecourse data show FOXP3+ Treg percentages in the Vβ11+ T cell population (values given at the top of each gate). 
***p < 0.001, **p < 0.01, NS: not significant. (c) Vβ11+ cells were analyzed for expression of FOXP3 and the binding of an APC-conjugated PC61 mAb to surface 
CD25. These data are representative of three independent experiments.
FigUre 10 | Continued  
A 2D2-FIG, MOG-specific FOXP3+ regulatory T cell (Treg) line exhibited in vitro and in vivo suppressive activities. (a,B) To prepare Tregs and a control line, CD45.2 
2D2-FIG FOXP3+ Tregs were cultured in PC61 and IL-2 for either 13 or 40 days, and CD45.2 2D2-FIG conventional T cells (Tcons) were cultured in IL-2 for 13 days. 
To test the ability of Tregs to suppress naïve T cell activation, 25,000 CD45.2 2D2-FIG Tregs or 25,000 CD45.2 2D2-FIG Tcons were co-cultured with 150,000 
CTV-stained CD45.1 2D2-FIG SPL responders for 5 days with 1 µM MOG35-55 and IL-2 (200 µl cRPMI). (a) CTV dye dilution and (B) percent suppression of 
CD45.1-gated responder T cells were analyzed by one-way ANOVA (n = 3). (c–g) A continuous line of FOXP3+ Tregs was activated with irradiated splenic APC, 
1 µM MOG35-55, IL-2, and 100 pM TGF-β for 3 days. The PC61 monoclonal antibody was not added to these cultures to avoid adoptive transfer of antibody-
coated T cells. Activated Tregs were cultured one additional day in IL-2 and were analyzed for expression of CD25 (clone 3C7) (c), surface-bound PC61 (anti-rat 
IgG) (D), and CD44 and CD62L (e). Tregs were extensively washed and injected (3 × 106/mouse) into naïve recipients on day −1. Recipients were then challenged 
with 100 µg MOG35-55 in CFA on day 0 and were given Pertussis toxin on days 0 and 2 to elicit experimental autoimmune encephalomyelitis (EAE). Significant 
differences (p < 0.05) were noted for the mean daily EAE scores on days 9–13 and 15–21 (F) and for daily weight loss on days 11–20. (h,i) EAE was elicited by 
administering 200 µg MOG35-55 in CFA on day 0 and Pertussis toxin on days 0 and 2. At peak disease (day 15, indicated by black arrow), activated 2D2 Tregs 
(3 × 106/mouse) were administered i.v. by retro-orbital injection. Significant differences (p < 0.05) were noted for mean daily EAE scores on days 18–28 (h) and for 
daily weight loss on days 21–28 (i).
17
Wilkinson et al. CD25 Antagonism Enables Treg Dominance
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1782
such that the cultured T  cell population may acquire immune 
effector functions rather than suppressive regulation activity. This 
study provides an exquisitely simple solution to this problem. 
Addition of the anti-mouse CD25 antibody PC61 to a mixed 
culture of TGF-β-iTregs and Tcons in the presence of IL-2 led to 
the rapid establishment of cultures dominated by Tregs (>90% 
Tregs). This approach did not depend upon genetic modification 
or physical purification. These Treg lines indefinitely sustained a 
Treg lineage phenotype when maintained with low concentrations 
of IL-2 and high concentrations of PC61 in continuous culture. 
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The Tregs derived in this study actively expanded and remained 
stable in the presence of PC61 and TGF-β in antigen-induced 
reactivation cultures, such that blastogenic Tregs expressed 
the prototypic Treg markers together with suppressive activity 
in vitro and in vivo.
elevated cD25 expression on Mature 
Tregs Provides an exploitable Treg 
Window
Previous studies showed that the potent IL-2 responsiveness of 
Tregs can be used to selectively promote Treg responses. For 
example, low-dose IL-2 therapies for type 1 diabetes selectively 
expanded existing Treg populations which could suppress islet 
cell destruction (8). Additionally, anti-IL-2 mAb/IL-2 immune 
complexes may target IL-2 to different T cell subsets depending on 
the epitope specificity of the anti-IL-2 mAb in the complex (14, 15, 
37). The JES6-1 anti-IL-2 mAb/IL-2 immune complex appeared 
to target IL-2 to Tregs to favor Treg expansion. Conversely, the 
S4B6 anti-IL-2 mAb/IL-2 complex favorably expanded effector 
T  cells by blocking the interaction between IL-2 and CD25. 
Advantages of targeting IL-2 versus CD25 have yet to be directly 
compared although targeting CD25, the Treg-specific component 
of the IL-2 receptor, may have qualitative advantages given the 
wide variations in endogenous IL-2 concentrations that may exist 
during chronic inflammatory autoimmune disease. Blockade of 
CD25 will predictably constrain IL-2 signaling across a broad IL-2 
concentration range, with an upper threshold defined by those 
levels of IL-2 sufficient for CD25-independent IL2Rβγ signaling. 
That is, even with widely varying concentrations of IL-2 and cell 
surface CD25, mAb-mediated blockade of CD25 may provide 
a reliable clamp to ensure low-zone IL-2 signaling to promote 
dominant Treg responses.
The IL-2 concentration was instrumental in determining 
T cell subset dominance (Figures 6A,D). Low-intensity and high-
intensity IL-2 signaling, respectively, supported Treg or Tcon 
subset dominance. The relation between low-zone IL-2 signaling 
and Treg responses reflected superior CD25 expression and 
exquisite IL-2 sensitivity of Tregs. The relation between high-zone 
IL-2 signaling and Tcon subset dominance may reflect differences 
in the respective IL-2 signaling pathways. IL-2 signaling in Tregs 
is mediated primarily through the JAK/STAT pathway whereas 
IL-2 signaling in Tcon subsets is mediated robustly through both 
JAK/STAT and PI(3)K pathways. PTEN, the PI(3)K inhibitor, is 
selectively expressed in Tregs and is important in stabilizing the 
Treg phenotype (38), whereas PTEN is downregulated in Tcon 
subsets (39). Thus, IL-2 has superior potency for Tregs due to 
higher CD25 expression, which confers Treg dominance at low 
IL-2 concentrations. By contrast, IL-2 has superior efficacy for 
Tcons due to robust signaling through both JAK/STAT and 
PI(3)K pathways, which confers Tcon dominance at high IL-2 
concentrations. Thus, differential expression of CD25 and PI(3)
K signaling pathways provide qualitative distinctions in IL-2 
signaling pathways that are foundational for the specialized Treg 
and Tcon niches.
Chronic CD25 blockade was the key to exploitation of the 
Treg window and stabilization of FOXP3+ Tregs. However, 
anti-CD25 mAbs varied substantially in Treg stabilization 
activity. The mAb of choice for stabilization of mouse Tregs was 
PC61, which was a stronger inhibitor of IL-2-dependent pro-
liferation than the anti-CD25 mAbs 3C7 and 7D4 (Figure 5A). 
The use of PC61 in concert with low IL-2 concentrations 
provided the appropriate qualitative and quantitative signals 
necessary for stabilization of FOXP3 expression and mainte-
nance of the Treg phenotype. Although PC61 was not useful 
in initial activation of 2D2-FIG SPL with antigen and TGF-β, 
PC61 in concert with IL-2 was included in all subsequent cul-
tures including maintenance cultures and reactivation cultures. 
TGF-β was beneficial during the initial activation culture and 
in all subsequent reactivation cultures. Thus, PC61 worked 
in concert with IL-2 to maintain Tregs, and TGF-β worked 
in concert with MHCII-restricted antigen to stabilize Tregs 
during blastogenic expansion. PC61 was the technical tool that 
allowed exploitation of a Treg window, which was operationally 
defined by a low range of IL-2 signaling that enabled dominant 
outgrowth of stable FOXP3+ Tregs. If IL-2 concentrations in 
PC61-supplemented cultures exceeded this range, then PC61 
lacked Treg stabilization activity, and Tcon subsets dominated 
the culture.
An important consideration was whether PC61 mAb 
crosslinked CD25 to elicit qualitatively unique, non-canonical 
IL-2 signaling pathways to stabilize Tregs. CD25 has no known 
intracellular signaling activity, and IL-2 signaling is mediated 
through the cytoplasmic domains of CD122 and CD132 (40). 
Nonetheless, CD25 has a cytoplasmic domain, and CD25 
cross-linking may indirectly crosslink other associated proteins. 
Hence, our studies with intact PC61 mAb could not exclude the 
possibility that PC61 may qualitatively modulate IL-2 signaling 
to favor the Treg subset. To address this question, we derived 
a monomeric PC61scFv that lacked cross-linking activity. This 
monomeric PC61scFv had essentially the same activity as PC61 
mAb in Treg stabilization assays (Figure 11). These results sup-
port the conclusion that PC61 stabilizes Tregs primarily through 
preferential blockade of IL-2 signaling in Tcon subsets. Notably, 
the use of PC61 or PC61scFv was fully sufficient for derivation of 
long-term stable FOXP3+ Treg lines without any physical puri-
fication or genetic modification. The use of suitable anti-CD25 
reagents could be used to guide formulation of culture conditions 
suitable for derivation of enriched Treg populations in large cul-
ture settings or bioreactors.
low-Zone il-2 signaling confers Treg 
stability
The IL-2 pathway is critical for self-tolerance in that genetic 
deficiencies in the major components of the IL-2/CD25/IL2Rβγ/
STAT5/JAK3 pathway result in systemic autoimmunity (41–46). 
The paradox is that IL-2 is the prototypic T cell growth factor 
in  vitro that drives dominant outgrowth of CD4+ and CD8+ 
effector lineages. Several studies showed that IL-2 is required for 
induction and maintenance of FOXP3 expression in Tregs (47), 
but IL-2 also drives proliferation of Tcons and destabilization of 
Treg populations (Figures 2 and 6). This study provides insight 
into the “IL-2 paradox” by showing that continuous culture of 
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Tregs in IL-2 and PC61 resulted in maintenance of high levels of 
FOXP3 expression and Treg stability for more than 60 days with-
out any phenotypic or functional attenuation (Figure 7). Indeed, 
continuous culture in IL-2 and PC61 appeared to promote a 
canonical Treg phenotype as measured by progressive increases 
in the expression of Helios and Neuropilin-1 (Figure 7). These 
findings provide suggestive evidence that the duration of a Treg 
phenotype might be associated with progressive stabilization 
of a FOXP3+ Treg phenotype, such that Tregs may gravitate 
to a more differentiated phenotype with time. If continuous 
low-zone IL-2 signaling in the context of a Treg window is key 
for understanding stabilization of FOXP3+ Tregs in  vitro, the 
implication is that continuous low-zone IL-2 signaling may also 
be key for maintenance and progressive differentiation of Tregs 
in vivo.
TGF-β was also required for Treg stability, but only in the 
context of MHCII-restricted antigen presentation by splenic APC 
in activation-dependent expansion cultures. TGF-β had no effect 
in maintenance cultures when added during propagation in IL-2 
with or without PC61. In reactivation cultures, a TGF-β-blocking 
antibody led to accelerated Treg destabilization, whereas addition 
of exogenous TGF-β preserved FOXP3 expression and FOXP3+ 
Treg percentages at optimal levels (Figure 8). In reactivation cul-
tures that included IL-2 and TGF-β, Tregs expanded more than 
fivefold without loss of FOXP3 as both a percentage of the T cell 
population and on a per cell basis based on MFI. The concentra-
tion of TGF-β in the reactivation culture was tailored to the TCR 
strength for cognate antigen of the particular clonotype. In other 
words, the correct balance of TGF-β, antigen, and IL-2 was neces-
sary for optimal expansion of Tregs and maintenance of the Treg 
phenotype. For example, 100 pM TGF-β was sufficient for expan-
sion of stable MOG-specific Tregs, which represents a low affinity 
clonotype. Higher concentrations of TGF-β (1 nM) were needed 
for optimal expansion of stable OVA-specific Tregs, which exhib-
its much stronger antigenic potency. Thus, TGF-β was needed in 
sufficient concentrations to counter-balance antigenic strength 
but these TGF-β concentrations had to be below thresholds that 
completely blocked the antigenic response. Thus, like the Treg 
window established for PC61/IL-2 in maintenance cultures, an 
appropriate range of TGF-β concentrations was needed for opti-
mal stabilization of Tregs during antigen-reactivated expansion 
cultures.
For both IL-2 and PC61 in maintenance cultures and TGF-β 
in reactivation cultures, a major question was whether Treg 
stabilization reflected the intrinsic stabilization of FOXP3 
expression or whether differential growth (or death) rates in 
Treg and Tcon subsets determined final Treg percentages. The 
most likely scenario is that both mechanisms contributed in part 
to the derivation of continuous Treg lines. For example, Tregs 
cultured in the presence of PC61 and IL-2 had higher FOXP3 
expression on a per cell basis than Tregs cultured in IL-2 alone, 
and Tregs cultured in PC61 and IL-2 also had higher growth 
rates than the Tcon subsets. PC61 may suppress Tcon prolifera-
tion which in turn may suppress secretion of pro-inflammatory 
cytokines that could antagonize TGF-β and destabilize FOXP3. 
These considerations may reflect a fundamental competition 
between these T cell subsets, wherein Treg subsets inhibit Tcon 
subsets, and Tcon subsets inhibit Treg subsets via mechanisms 
of reciprocal inhibition.
An important caveat is that this study pertains to the MOG-
specific 2D2 clonotype, the OVA-specific OTII clonotype, and 
mitogen-activated polyclonal C57BL/6 T  cells. The kinetics by 
which PC61 selects for CD25high Tregs will be determined in part 
by the relative proportion and persistence of CD25high Treg and 
Tcon subsets in the cell preparation, which may vary in differ-
ent T  cell preparations. Although PC61/IL-2 selection exploits 
qualitative distinctions in CD25 expression in Treg and Tcon 
subsets, stronger antigenic or mitogenic stimuli may cause more 
persistent CD25 expression in Tcon subsets which may necessitate 
longer periods of PC61/IL-2 selection to achieve FOXP3+ Treg 
dominance. PC61-mediated Treg selection therefore may vary in 
kinetics based on the inherent antigenic reactivity of the relevant 
clonotype. A second caveat is that PC61/IL-2 selects CD25high 
FOXP3+ subsets at the expense of CD25low FOXP3+ subsets. For 
example, pre-existing Tregs isolated from secondary lymphoid 
organs express CD25 across a quantitative continuum, and PC61/
IL-2 selects the CD25high subset that represents the functionally 
mature suppressive subset.
cOnclUsiOn
This study defined an operative “Treg niche” defined by low-
zone IL-2 signaling. This study also provided a strategy for 
maintenance and expansion of stable FOXP3+ Treg lines in vitro, 
which could be propagated indefinitely without phenotypic 
instability. These principles were validated for TGF-β-inducible 
Tregs, which may be optimal for derivation of antigen-specific 
Tregs from peripheral blood. Although we assume that these 
principles would also apply to thymic or natural tTreg/nTregs, 
this issue awaits future study. Overall, this strategy could be 
applied broadly to Tregs of any clonotypic specificity and thereby 
may have applicability for the advancement of antigen-specific 
Treg-based immunotherapies.
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